Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA
Post by: Tina Gaines
Elanco Canada has recently received approval from Health Canada for expanded respiratory disease treatment coverage for Pulmotil® AC.
Pulmotil® AC, licensed in Canada since October 2012, is a water soluble antibiotic used for the reduction in severity of swine respiratory disease associated with Actinobacillus pleurpneumoniae and Pasteurella multiocida. Pulmotil® AC is administered in Canada solely under the direction of a veterinary prescription. Full label information is available in the Compendium of Veterinary Products.
A 2015 efficacy trial compared lung lesions in pigs co-infected with Mycoplasma hyopneumoniae and PRRS virus. Results showed a 26% reduction in lung lesions in pigs treated with Pulmotil® AC at the label dosage during the infection period.1 A second efficacy trial showed a significant improvement in recovery rate of pigs treated with Pulmotil® AC at the label dosage in the presence of naturally occurring infection with Pasteurella multocida and Haemophilus parasuis.2
“Elanco Canada is pleased to announce these additional indications to our Pulmotil® AC label. These new indications support our veterinary customer with effective and convenient product solutions for the control of respiratory diseases,” said Amber Swidersky, Elanco Canada Swine Sales Manager.
Dr. Randy Bagg, Elanco Canada Director of Regulatory Affairs and Research, commented “We continue to invest in existing products, as well as, new innovations to ensure we provide our customers with solutions within the Canadian Regulatory System for responsible antibiotic usage.”
Pulmotil AC Important Safety Information
Caution: Treated swine must not be slaughtered for use in food for at least 8 days after the latest treatment with this drug.
Do not allow horses or other equines access to drinking water containing tilmicosin.
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.ca and EnoughMovement.com.
Elanco internal 2015 study data on file.
Elanco internal 2012 study data on file.
Elanco™, Pulmotil®, and the diagonal bar are trademarks owned by or licensed to Eli Lilly and Company, its affiliates or subsidiaries.
© 2016 Eli Lily and Company, or its affiliates.
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.